Trial Number
138-21
Condition
Leukemia
Participant Age Range
18 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment with Bruton’s Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib”
Data will be collected from CLL patients in the US who initiated acalabrutinib mono or combination therapy with an anti-CD20 monoclonal antibody (mAb) or ibrutinib mono- or combination therapy with an anti-CD20 mAb within 7 days (before or after) of study enrollment. The study will include both first line of therapy (1LOT) and relapsed/refractory (r/r) CLL patients.